NIMH Clinical Study
NIMH AV-101 Phase 2 Monotherapy Study for MDD
The U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH), is currently evaluating AV-101 in a Phase 2 monotherapy study for the treatment of MDD. This study is being conducted and funded by the Dr. Carlos Zarate of the NIMH. AV-101 has a novel mechanism of action (MOA), meaning its MOA is fundamentally different from all current FDA-approved treatments for depression, with potential to further drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. VistaGen's development strategy for AV-101 is focused on establishing it as the primary augmentation option for patients with MDD having an inadequate response to current, FDA-approved antidepressants, displacing adjunctive use of atypical antipsychotics such as aripiprazole in the current depression treatment paradigm.
Study Center and Contact
|National Institutes of Health Clinical Center
9000 Rockville Pike
Bethesda, MD 20892
|Carlos A Zarate, M.D.|
For more information about the study, please visit www.clinicaltrials.gov.